fr
Article scientifique
Anglais

The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice

Publié dansSurgery, vol. 150, no. 1, p. 48-55
Date de publication2011
Résumé

Islet transplantation has become a viable option for selected type 1 diabetic patients; however, a significant portion need to return to exogenous insulin. The predominant factors include impaired islet engraftment and early islet loss. Caspase inhibition is a potent way to improve islet engraftment, but all tested compounds so far have not been clinically relevant. IDN-6556 (PF3491390) has already been used clinically and can be delivered orally with high portal vein concentrations.

Mots-clés
  • Animals
  • Apoptosis/drug effects
  • Blood Glucose/metabolism
  • Caspases/antagonists & inhibitors
  • Cysteine Proteinase Inhibitors/pharmacology
  • Diabetes Mellitus, Experimental/blood/drug therapy/surgery
  • Glucose Tolerance Test
  • Graft Enhancement, Immunologic/methods
  • Graft Survival/drug effects
  • Humans
  • Islets of Langerhans Transplantation/pathology/physiology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Pentanoic Acids/pharmacology
  • Transplantation, Heterologous
  • Transplantation, Isogeneic
Citation (format ISO)
MCCALL, Michael et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. In: Surgery, 2011, vol. 150, n° 1, p. 48–55. doi: 10.1016/j.surg.2011.02.023
Fichiers principaux (1)
Article (Published version)
accessLevelRestricted
Identifiants
ISSN du journal0039-6060
580vues
0téléchargements

Informations techniques

Création08/11/2012 16:13:00
Première validation08/11/2012 16:13:00
Heure de mise à jour14/03/2023 17:49:15
Changement de statut14/03/2023 17:49:15
Dernière indexation16/01/2024 00:45:11
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack